Comparison of three antithrombotic strategies for emergent carotid stenting during stroke thrombectomy: a multicenter study

J Neurointerv Surg. 2023 Dec 21;15(e3):e388-e395. doi: 10.1136/jnis-2022-019875.

Abstract

Background: Periprocedural antithrombotic treatment is a key determinant for the risk-benefit balance of emergent carotid artery stenting (eCAS) during stroke thrombectomy. We aimed to assess the safety and efficacy of three types of antithrombotic treatment.

Methods: Retrospective review of prospectively collected endovascular databases in four comprehensive stroke centers, including consecutive cases of eCAS for tandem lesion strokes between January 2019 and July 2021. During this period, each center prospectively applied one of three periprocedural protocols: (a) two centers administered aspirin (250 mg IV); (b) one center administered aspirin and heparin (bolus+24 hours infusion); and (c) one center applied an aggressive antiplatelet strategy consisting of aspirin and clopidogrel (loading doses), with added intravenous tirofiban if in-stent thrombosis was observed during thrombectomy. Dichotomized comparisons of outcomes were performed between aggressive versus non-aggressive strategy (aspirin±heparin) and aspirin+heparin versus aspirin-alone groups.

Results: Among 161 included patients, 62 received aspirin monotherapy, 38 aspirin+heparin, and 61 an aggressive treatment. Aggressive antiplatelet treatment was associated with an increased rate of excellent (modified Thrombolysis in Cerebral Infarction (mTICI) 2c-3) recanalization and reduced carotid stent thrombosis at day 1 (3.5% vs 16.3%), compared with non-aggressive strategy. There were no significant differences in hemorrhagic transformation or 90-day mortality. There was a tendency towards better clinical outcome with aggressive treatment, without reaching statistical significance. Addition of heparin to aspirin was not associated with an increased rate of carotid stent patency.

Conclusions: Aggressive antiplatelet treatment was associated with improved intracranial recanalization and carotid stent patency, without safety concerns. These findings have implications for randomized trials and may be of utility for clinicians when making antithrombotic treatment choices.

Keywords: Cervical; Platelets; Stent; Stroke; Thrombectomy.

Publication types

  • Multicenter Study

MeSH terms

  • Aspirin / therapeutic use
  • Carotid Stenosis* / diagnostic imaging
  • Carotid Stenosis* / drug therapy
  • Carotid Stenosis* / surgery
  • Endovascular Procedures* / adverse effects
  • Fibrinolytic Agents
  • Heparin
  • Humans
  • Retrospective Studies
  • Stents / adverse effects
  • Stroke* / diagnostic imaging
  • Stroke* / drug therapy
  • Stroke* / surgery
  • Thrombectomy / adverse effects
  • Thrombosis* / etiology
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Aspirin
  • Heparin